quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·49d
PRRelease
Silence Therapeutics Plc logo

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

SLN· Silence Therapeutics Plc
Health Care
Original source

Companies

  • SLN
    Silence Therapeutics Plc
    Health Care

Recent analyst ratings

  • Feb 11UpdateGoldman$6.00
  • Dec 2UpdateBMO Capital Markets-
  • Sep 3UpdateJefferies$40.00
  • Jan 31UpdateBMO Capital Markets$67.00
  • May 8UpdateMorgan Stanley$20.00
  • Dec 9UpdateMorgan Stanley$18.00

Related

  • SEC49d
    SEC Form S-8 filed by Silence Therapeutics Plc
  • SEC49d
    SEC Form 10-K filed by Silence Therapeutics Plc
  • SEC49d
    Silence Therapeutics Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
  • INSIDER69d
    SEC Form 4 filed by Large owner Griffiths Richard Ian
  • INSIDER107d
    SEC Form 4 filed by Director Ede-Golightly James
  • INSIDER107d
    SEC Form 4 filed by EVP and Chief R&D Officer Romano Steven J.
  • INSIDER107d
    SEC Form 4 filed by Director Mcinerney Timothy
  • INSIDER107d
    SEC Form 4 filed by Director Lemus David
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022